1. Academic Validation
  2. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship

  • J Med Chem. 2006 Jul 13;49(14):4425-36. doi: 10.1021/jm0602413.
Donn G Wishka 1 Daniel P Walker Karen M Yates Steven C Reitz Shaojuan Jia Jason K Myers Kirk L Olson E Jon Jacobsen Mark L Wolfe Vincent E Groppi Alexander J Hanchar Bruce A Thornburgh Luz A Cortes-Burgos Erik H F Wong Brian A Staton Thomas J Raub Nicole R Higdon Theron M Wall Raymond S Hurst Rodney R Walters William E Hoffmann Mihaly Hajos Stanley Franklin Galen Carey Lisa H Gold Karen K Cook Steven B Sands Sabrina X Zhao John R Soglia Amit S Kalgutkar Stephen P Arneric Bruce N Rogers
Affiliations

Affiliation

  • 1 Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, USA.
Abstract

N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha7 neuronal nicotinic acetylcholine receptor (alpha7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective alpha7 nAChR Agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.

Figures
Products